Methyl Acetate Boosts the Low-Temperature Performance of Li4Ti5O12/Graphite Dual-Ion Batteries.

Methyl acetate (MA) is a suitable solvent for low-temperature electrolyte solutions, but its poor stability against lithium metal is a big problem. Herein, a simple and cheap solution of LiPF6 dissolved in MA was successfully employed for Li4Ti5O12/graphite dual-ion batteries (DIBs). This cell has a long cycle life with 93.1% capacity retention after 1000 cycles. Moreover, it has superior performance at low temperatures (-40 °C) compared to other reported DIBs. The storage behavior of PF6- solvated by MA in graphite cathode has been investigated in detail by in situ X-ray diffraction (XRD) in combination with electrochemical dilatometry (ECD).

Fluorinated Polyethylenimine and Fluorinated Choline Phosphate Lipids Complex System for Efficient mRNA Delivery to Deep-Seated Tumor Tissues.

Efficiently delivering mRNA to the deep-seated cells of diseased tissues for therapeutic purposes remains a significant challenge. To address this, we leveraged the dual hydrophobic properties of fluorine atoms to conjugate fluorinated polyethylenimine (FPEI) with fluorinated choline phosphate (FCP) lipids. When one adjusted the ratio of N/F atoms to 2/1 and a 15% FCP content, the mRNA@FPEI-FCP carrier was optimized, achieving significant circulation and accumulation in deep tumor regions. Compared to control carriers lacking FCP or FPEI, mRNA@FPEI-FCP exhibited a 3.94-fold increase in tumor targeting and a 3.0-fold increase in deep delivery. Delivery of IL-2 mRNA to 4T1 breast tumors resulted in a tumor inhibition rate of 91.9%, with IL-2 levels reaching 149.2 pg/mL and 12.1% of CD4+ cells throughout the tumor, with no abnormal blood indexes. This FPEI and FCP composite delivery system demonstrates potent targeting of mRNA delivery to deep tumor tissues.

Infrared Responsive Choline Phosphate Lipids for Synergistic Cancer Therapy.

Choline phosphate lipids have been designed and developed as new-generation zwitterionic nanocarriers with excellent biocompatibility and bioorthogonality to provide a more programmable performance for cancer therapy. However, there is a lack of spatiotemporal and reversible control for drug release at target tumor cells, which can lead to severe adverse effects to normal tissue and discounted treatment outcome. Here, light-inducible Lip-cRGDfk/ICG/Dox liposomes were developed for synergistic cancer therapy. ICG can effectively convert light energy into selective heating in a local environment upon laser irradiation, thus inducing thermal ablation of tumor cells, and further reversibly trigger the spatiotemporal release of anticancer drugs (Dox) at tumor cells due to the conformation transformation of CP lipids to synergistically kill tumor cells. That Lip-cRGDfk/ICG/Dox exhibited a significant improvement for breast cancer therapy in vitro and in vivo is also demonstrated, thus it can serve as an efficient platform to noninvasively and spatiotemporally control the activation of cytotoxicity at tumor cells for precision cancer therapy.

Choline phosphate lipid as an intra-crosslinker in liposomes for drug and antibody delivery under guard.

Liposomes are used to deliver therapeutics in vivo because of their good biocompatibility, efficient delivery, and ability to protect the therapeutics from degradation. However, the instability of liposomes will cause the therapeutics to lose protection and become ineffective. To deliver therapeutics to the target under guard, we synthesized and used a bio-membrane mimetic choline phosphate lipid (CP-lip) to intra-crosslink liposomes to highly improve their stability. We found that when the ratio of PC-lip to CP-lip is 1 : 2, the intra-crosslinked liposome (PC-CP-lipo) showed higher stability, better biocompatibility and improved anti-protein adsorption than other common liposomes. We used doxorubicin (Dox) loaded PC-CP-lipo to treat melanoma and the tumor inhibition ratio could reach 86.3%. After the combined Dox@PC-CP-lipo treatment with PD-L1 antibody to block the immune checkpoints, the tumor suppression rate could reach 94.4%, and 60% of the mice did not suffer from tumor rechallenge. The method of using a CP-lip to intra-crosslink liposomes is applicable to all liposomes, solving the key problem of liposome disintegration, thus enhancing the protection of drugs and antibodies by liposomes in vivo.

Choline phosphate lipid insertion and rigidification of cell membranes for targeted cancer chemo-immunotherapy.

To prevent tumor reproduction and metastasis, a method to modify the membranes of cancer cells was designed to suppress their vitality. A phosphatidyl choline reversed choline phosphate lipid (CP-Lip) was synthesized and modified with a PD-L1 antibody (CP-αPDL). Drug-loaded nanoparticles of CP-Lip/CP-αPDL (Dox@tCP-Lipos) could be selectively attached to melanoma cells, thus causing CP-Lip to be inserted and to interact strongly with the cell membrane, which largely reduced the fluidity and functionality of the membrane. As a result, the metabolism, reproduction, and migration of melanoma cells were proved to be weakened by CP-Lip and the tumor was 100% suppressed after treatment with Dox@tCP-Lipos.